Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)
Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Laura Mezquita(Hospital Clínic de Barcelona), Víctor Albarrán-Artahona(Institut Gustave Roussy), Giancarlo Castellano(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Benjamin Besse(Université Paris-Sud), Alejandro Navarro(Vall d'Hebron Hospital Universitari), M.C. Batanero Bernabeu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Édouard Auclin(Centre Hospitalier de l’Université de Montréal), Gerard Caravaca(Hospital Clínic de Barcelona), Pilar Garrido(Hospital Universitario Ramón y Cajal), A. Arcocha(Hospital Clínic de Barcelona), Joan Sart(Hospital Clínic de Barcelona), Javier Elío(Western Norway University of Applied Sciences), Juan Carlos Laguna(Hospital Clínic de Barcelona), Miquel Ferriol-Galmés(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Teresa Gorría(Hospital Clínic de Barcelona), Alex Martínez Bedmar, Noemı́ Reguart(Hospital Clínic de Barcelona), Aleix Prat(Breast Cancer Research Foundation), Rafael López Castro(Hospital Clínico Universitario de Valladolid), Manuel Jiménez(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Laura Alcolea(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Natasha B. Leighl(University Health Network), Marta García de Herreros(Hospital Clínic de Barcelona), David Delgado-Cano(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Cristina Teixidó(Hospital Clínic de Barcelona)
Cited by 2
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k